Experimental Treatment for Neurofibromatosis Type 1 Earns Orphan Drug Designation in the EU
<a href="https://pixabay.com/users/pixel2013/">pixel2013</a> / Pixabay

Experimental Treatment for Neurofibromatosis Type 1 Earns Orphan Drug Designation in the EU

According to a story from BioPortfolio, the biopharmaceutical company SpringWorks Therapeutics, Inc., has recently announced that the European Commission has given the company's investigational drug candidate mirdametinib Orphan Drug designation.…

Continue Reading
  • 1
  • 2
Close Menu